39263-34-8

Usage

Uses

Used in Organic Synthesis:
N'-(2-CYANO-4-NITROPHENYL)-N,N-DIMETHYLIMINOFORMAMIDE is used as a reagent in organic synthesis for its ability to participate in various chemical reactions, facilitating the creation of a wide range of organic compounds.
Used in Pharmaceutical Production:
In the pharmaceutical industry, N'-(2-CYANO-4-NITROPHENYL)-N,N-DIMETHYLIMINOFORMAMIDE is utilized as an intermediate. Its role is crucial in the synthesis of various medicinal compounds, contributing to the development of new drugs.
Used in Agrochemical Production:
Similarly, in agrochemical manufacturing, N'-(2-CYANO-4-NITROPHENYL)-N,N-DIMETHYLIMINOFORMAMIDE serves as an intermediate, playing a key part in the synthesis of chemicals used in agriculture to protect crops and enhance yields.
Given the compound's potential hazards, it is essential to handle, transport, and store N'-(2-CYANO-4-NITROPHENYL)-N,N-DIMETHYLIMINOFORMAMIDE according to the specified safety regulations to minimize risks of mutagenicity and irritation.

Upstream product

• 611-09-6 5-nitroisatin 
• 68-12-2 N,N-dimethyl-formamide 
• 49675-77-6 3-(hydroxyimino)-5-nitroindolin-2-one 
• 100-01-6 4-nitro-aniline 
• 17420-30-3 5-nitroanthranilonitrile 
• 17122-62-2 hydroxyimino-acetic acid-(4-nitro-anilide) 
• 91-56-5 indole-2,3-dione 

Downstream Products

• 1354795-61-1 N₆-(4-fluorobenzyl)-N₄-(3-bromophenyl)quinazoline-4,6-diamine 
• 1354795-62-2 N₆-(4-chlorobenzyl)-N₄-(3-bromophenyl)quinazoline-4,6-diamine 
• 1354795-63-3 N₆-(4-bromobenzyl)-N₄-(3-bromophenyl)quinazoline-4,6-diamine 
• 1354795-64-4 N₆-(2-chlorobenzyl)-N₄-(3-bromophenyl)quinazoline-4,6-diamine 
• 1354795-65-5 N₆-(2-bromobenzyl)-N₄-(3-bromophenyl)quinazoline-4,6-diamine 
• 1354795-66-6 N₆-(4-methoxybenzyl)-N₄-(3-bromophenyl)quinazoline-4,6-diamine 
• 1354795-67-7 2-((4-(3-chlorophenylamino)quinazolin-6-ylamino)methyl)phenol 
• 1354795-68-8 4-((4-(3-chlorophenylamino)quinazolin-6-ylamino)methyl)phenol 
• 1354795-69-9 N₇-(2-methoxybenzyl)-N₂-(3-chlorophenyl)quinazoline-2,7-diamine 
• 1354795-70-2 N₇-(4-fluorobenzyl)-N₂-(3-chlorophenyl)quinazoline-2,7-diamine 
• 1354795-71-3 N₆-(4-chlorobenzyl)-N₄-(3-chlorophenyl)quinazoline-4,6-diamine 
• 1354795-72-4 N₆-(4-bromobenzyl)-N₄-(3-chlorophenyl)quinazoline-4,6-diamine 
• 1354795-74-6 N₆-(2-bromobenzyl)-N₄-(3-chlorophenyl)quinazoline-4,6-diamine 

Relevant academic research and scientific papers

Large yellow acid anilinoquinazoline derivatives preparation and anti-tumor application

The invention discloses large yellow acid anilinoquinazoline derivatives preparation and for anti-tumor. In order to parietic acid as a lead compound, is introduced into the 4 - anilinoquinazoline structure, synthesis is contained and 1, 8 - [...] - 9, 10 - anthraquinone - N - (6 - amino - 4 - anilinoquinazoline) - 3 - carboxamides of the compound. Cell test Certificate, the class of compounds of the nasopharyngeal carcinoma cells, breast cancer cells, liver cancer cells and ovarian cancer cells with different degree suppression effect, can be used for anti-tumor pharmaceutical preparation.

Irbinitinib intermediates for preparation of (by machine translation)

The invention belongs to the organic synthesis and bulk drug preparation technology field, in particular to the treatment of breast cancer drug Irbinitinib preparation method and intermediate, comprising the steps of: 2 - methyl - 4 - nitro-phenol (formul

Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors

Series of 4-anilinoquinazoline derivatives were conveniently and efficiently synthesized and their antitumor activities were evaluated by MTT assay in three human cancer cell lines: H1975, HepG2 and SMMC-7721. New compounds 19a-19h were designed and synthesized to seek for powerful EGFR inhibitors and to explore whether methyl group at C-2 position of quinazoline ring has a positive effect on EGFR inhibition. All the compounds of 19a-19h were found potent against all three cell lines and five compounds (19c, 19d, and 19f-19h) were found more potent against H1975 than gefitinib. SAR studies revealed that methyl group at C-2 position of quinazoline ring could significantly improve the antitumor potency of 4-anilinoquinazolines. The same conclusion was also drawn according to the results of Western blotting analysis. Among all the tested compounds, 19g exhibited extremely potent against H1975 with an IC50 value of 0.11 μM, remarkably lower than that of gefitinib (1.23 μM). The results of western blotting analysis showed that compounds 19c and 19g could notably inhibit the expression of phosphorylated EGFR, especially 19g, almost inhibited completely.

A novel strategy to the synthesis of 4-anilinoquinazoline derivatives

A novel approach to prepare 4-anilinoquinazoline derivatives based on the transformation of indoline-2,3-dione to formamidine was developed. The processes with this approach are simple, efficient, and environmentally friendly. The efficiency of this approach was evaluated by synthesizing 17 4-anilinoquinazolines and comparing the obtained yields with those achievable through conventional synthetic methods. It was the first time that compounds 8d, 8e, 8h, and 13b-f were synthesized. The characteristics of the IR and the UV spectra of these compounds and the effects of their substituents on the spectra were observed.